


## Trading Update

### Record MetaXplore Sales, Milestone reached in MetaPanel Sales

Microba Life Sciences Limited (ASX:MAP) ("Microba" or "the Company") is pleased to announce a trading update ahead of the Company's AGM to be held later today at 11am (AEST) in Brisbane, the Chair, Deputy Chair and CEO addresses will be released separately ahead of the meeting.

#### Diagnostics Update:

- 1) Following record Australian MetaXplore sales in October, this strong growth momentum has continued into November
- 2) With 5 weeks remaining, H1FY25 YTD MetaXplore sales are already ahead of H2FY24. Q2FY25 annualised run rate of 11,000+ tests versus 7,238 in Q1FY25
- 3) MetaPanel doctor referrals and sales continuing to build across Australia, reaching a milestone in November of over 500 tests sold, since launch in Mar-24
- 4) Continued MetaPanel clinical adoption growth is expected to be accelerated by ongoing sales and marketing activities as well as upcoming clinical utility study results and associated publications
- 5) MetaXplore early access commenced in late October in the UK with first orders & samples received and associated reports delivered



#### Therapeutics Update:

- 6) On the back of recent progress across the Company's therapeutic programs, and as we progress MAP 315 to a Phase 2 clinical trial in IBD, the Company is active in a range of partnering activities evaluating various non-dilutive strategic opportunities and will update shareholders at the appropriate time.

#### Outlook:

- 7) Continued MetaXplore sales momentum in Australia
- 8) UK advancing into next phase of growth with recent doubling of sales staff supported by the appointment of Alaster Stockwell-Jones, ex Stryker, GE Healthcare and Eli Lilly as UK Commercial Director
- 9) Work continues to advance on the pathway to USA reimbursement
- 10) Commencement of Phase 2 clinical trial in IBD for MAP 315 dependent on partnering activities
- 11) Cash and equivalents balance as at 26-Nov of \$19.5m (unaudited)

Shareholders wishing to attend the Annual General Meeting in person can find the details in the Notice of Meeting as lodged with the ASX on 28 October 2024 and available at the Company's website at

<https://ir.microba.com/announcements/6599303>

View this announcement on our Investor Hub: <https://ir.microba.com/link/NPwRGr>



#### JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit [ir.microba.com/welcome](https://ir.microba.com/welcome)

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621

*This announcement has been authorised for release by the Chair and Chief Executive Officer.*

For further information, please contact:

**Dr Luke Reid**

Chief Executive Officer

[luke.reid@microba.com](mailto:luke.reid@microba.com)

**Investor / Media Relations**

[investor@microba.com](mailto:investor@microba.com)

<https://ir.microba.com/welcome>

**About Microba Life Sciences Limited**

Microba Life Sciences is a company at the forefront of microbiome diagnostics & therapeutics and are on a mission to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit [www.microba.com](http://www.microba.com)

For personal use only



**JOIN MICROBA'S INTERACTIVE INVESTOR HUB**

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit [ir.microba.com/welcome](http://ir.microba.com/welcome)

**Microba Life Sciences Ltd** | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621